[18F]NAV4694

DRUG3 trials

Sponsors

Navidea Biopharmaceuticals

Conditions

Alzheimer DiseaseAlzheimer's DiseaseDementiaMild Cognitive Impairment

Phase 2

Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease

Navidea BiopharmaceuticalsAlzheimer Disease

Start: 2012-08-31End: 2018-12-31Target: 70Updated: 2016-03-30

Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI

TerminatedNCT01812213

Navidea BiopharmaceuticalsMild Cognitive Impairment

Start: 2013-03-31End: 2017-11-02Updated: 2024-08-14

Phase 3

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

Navidea BiopharmaceuticalsAlzheimer's Disease, Dementia

Start: 2013-06-30End: 2018-09-30Target: 290Updated: 2017-07-26